Personal genomics: New drugs target common cancers

| September 10, 2012
lungs
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.
Tens of thousands of Americans with tumors from certain types of lung cancer have mutations that might be treated by new drugs that are already in the pipeline or that could be easily developed–a dramatic demonstration of the promise of personalized genomic-based medicine.
Additional Resources:

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend